Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib

Jacqueline Fischer, Estelle Erkner, Pia Radszuweit, Thomas Hentrich, Hildegard Keppeler, Fulya Korkmaz, Julia Schulze-Hentrich, Rahel Fitzel, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind · 2024

Read Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib by Jacqueline Fischer, Estelle Erkner, Pia Radszuweit, Thomas Hentrich, Hildegard Keppeler, Fulya Korkmaz, Julia Schulze-Hentrich, Rahel Fitzel, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641557.txt.

Description

Jacqueline Fischer and co-authors test, in 2024, whether a cancer drug works differently in infant and adult forms of one leukemia. The leukemia is driven by a rearranged gene and has a poor outlook. The drug blocks an enzyme that helps cells divide, and it had shown limited success in adults.

Using lab models built from cord blood and adult marrow, the team found the enzyme was much higher in the infant model. The drug slowed growth and halted the cell cycle most in that model. Adult cells fought back by raising related genes, but a second drug overcame that defense. Cell origin should guide treatment choices, the authors argue.

Catalog record

CREATORJacqueline Fischer, Estelle Erkner, Pia Radszuweit, Thomas Hentrich, Hildegard Keppeler, Fulya Korkmaz, Julia Schulze-Hentrich, Rahel Fitzel, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11641557

Browse the full library · About the Tower of Babel